Bristol Myers insider sells 6,249 shares at $64.57

Rhea-AI Filing Summary

BRISTOL MYERS SQUIBB CO (BMY) reported that executive officer Cristian Massacesi, EVP, Chief Medical Officer and Head of Development, sold 6,249 shares of common stock on September 9, 2026 in a sale described as an open market or private transaction at $64.57 per share. After this transaction, he directly holds 18,748 shares of Bristol Myers Squibb common stock, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 6,249 shares

Net Sell 1 txn

Insider Massacesi Cristian

Role EVP,Chief Med Offr,Head of Dev

Sold 6,249 shs ($403K)

Type	Security	Shares	Price	Value
Sale	Common Stock, $0.10 par value	6,249	$64.57	$403K

Holdings After Transaction: Common Stock, $0.10 par value — 18,748 shares (Direct)

Key Figures

Shares sold: 6,249 shares Sale price per share: $64.57 per share Shares held after transaction: 18,748 shares +2 more

5 metrics

Shares sold 6,249 shares Common stock sold by Cristian Massacesi on September 9, 2026

Sale price per share $64.57 per share Price for the 6,249 BMY shares sold on September 9, 2026

Shares held after transaction 18,748 shares Direct ownership of BMY common stock by Cristian Massacesi after the sale

Transactions reported as sales 1 transaction Number of sale transactions in this Form 4

Net buy/sell shares 6,249 shares net sold Net change in common stock holdings reported in this filing

Key Terms

Common Stock, $0.10 par value, Rule 10b5-1 trading plan, open market or private transaction

3 terms

Common Stock, $0.10 par value financial

"The transaction involved Common Stock, $0.10 par value of Bristol Myers Squibb."

Rule 10b5-1 trading plan regulatory

"No Rule 10b5-1 trading plan is reported in connection with this sale."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction financial

"The sale is described as a sale in open market or private transaction."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BMY report for Cristian Massacesi on September 9, 2026?

Bristol Myers Squibb reported that Cristian Massacesi sold 6,249 shares of common stock on September 9, 2026 in a transaction described as a sale in an open market or private transaction at $64.57 per share.

How many BMY shares does Cristian Massacesi hold after the reported sale?

After the reported sale, Cristian Massacesi directly holds 18,748 shares of Bristol Myers Squibb common stock. This figure is disclosed as his total direct ownership following the September 9, 2026 transaction.

Was the September 9, 2026 BMY insider sale made under a Rule 10b5-1 plan?

No. The Form 4 indicates that the Rule 10b5-1 trading plan box is not checked, and there is no footnote stating that the 6,249-share sale by Cristian Massacesi was made pursuant to a Rule 10b5-1 or similar pre-arranged trading plan.

What price did Cristian Massacesi receive per BMY share in the September 9, 2026 sale?

The reported sale by Cristian Massacesi of 6,249 shares of Bristol Myers Squibb common stock on September 9, 2026 was executed at a price of $64.57 per share, stated as a per-share transaction price.

What type of security did Cristian Massacesi sell in this BMY Form 4 filing?

The transaction involved Common Stock, $0.10 par value of Bristol Myers Squibb. The Form 4 reports a sale of 6,249 shares of this common stock class on September 9, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:37 PM Accepted by SEC EDGAR 09/10/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Massacesi Cristian

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NEW JERSEY 08543

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP,Chief Med Offr,Head of Dev

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.10 par value	09/09/2026		S		6,249	D	$64.57	18,748	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Amy Fallone, attorney-in-fact for Cristian Massacesi	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)